Comparing applets and oranges: barriers to evidence-based practice for app-based psychological interventions
Published in: BMJ Evidence-based mental health
Poor-quality pharmaceuticals and medical devices rarely make it to market; however, the same cannot be said for app-based interventions. With a high availability but low evidence base for mHealth, apps are an increasingly uncertain prospect to users and healthcare professionals alike.
Although in a first-best situation, the burden of proof concerning app safety, clinical and cost-effectiveness ‘should’ ultimately lie with app developers; a number of barriers to evidence generation, including the fact that ‘acceptable evidence’ itself is largely open to interpretation, mean that it may be folly to expect this paucity of real-world effectiveness research to improve.
While the health technology assessment of established therapeutic modalities including pharmaceuticals and talking therapies benefits from the existence of approved evaluative guidelines, unfortunately the same cannot be said for app-based interventions, specifically with regard to outcomes measurement.
As such, it would seem that in order to prevent the comparative assessment of apps simply becoming an exercise comparing apples and oranges, there is a clear need for consensus and guidance for app developers, as to which patient-reported outcome measures, among the hundreds available, are of clinical use to those making decisions, and should therefore be used when developing app-based interventions.
By negating the fear that any evidence collected may be of poor quality, we can reincentivise developers to engage in evidence generation, and in doing so, maximise the likelihood of evidence-based decision-making taking a firm hold. However, only by dispelling the ambiguity around what acceptable evidence can and should look like, can we begin to do so.
Read the full research piece here: https://ebmh.bmj.com/content/ebmental/19/3/90.full.pdf
Digital health sector will take advantage of landmark new UK-Australia Free Trade Agreement
Digital health companies ORCHA and Cogniss have announced a global partnership that will benefit from the new UK-Australian Free Trade Agreement (FTA) which has just passed through the UK House of Commons and is anticipated to come into effect in 2023.
Founded by NHS clinicians, ORCHA is the world’s leading digital health evaluation and distribution organisation. We provide services to national health bodies across three continents, including the NHS in 50% of UK regions, delivering national accreditation frameworks, bespoke Digital Health Libraries, and professional recommendation tools, specific to the needs of our clients. ORCHA’s unique Review Engine assesses digital health solutions against more than 350 measures across Clinical/Professional Assurance, Data u0026amp; Privacy, and Usability u0026amp; Accessibility, plus additional criteria depending on needs.
Oops! We could not locate your form.